These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35497510)

  • 21. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virtual screening and molecular dynamics simulation analysis of Forsythoside A as a plant-derived inhibitor of SARS-CoV-2 3CLpro.
    Bibi S; Khan MS; El-Kafrawy SA; Alandijany TA; El-Daly MM; Yousafi Q; Fatima D; Faizo AA; Bajrai LH; Azhar EI
    Saudi Pharm J; 2022 Jul; 30(7):979-1002. PubMed ID: 35637849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into the Dynamics and Binding of Two Polyprotein Substrate Cleavage Points in the Context of the SARS-CoV-2 Main and Papain-like Proteases.
    Sanusi ZK; Lobb KA
    Molecules; 2022 Nov; 27(23):. PubMed ID: 36500348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
    Jamalan M; Barzegari E; Gholami-Borujeni F
    J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: Insight from quantum mechanical evaluation and molecular modeling.
    Balogun TA; Chukwudozie OS; Ogbodo UC; Junaid IO; Sunday OA; Ige OM; Aborode AT; Akintayo AD; Oluwarotimi EA; Oluwafemi IO; Saibu OA; Chuckwuemaka P; Omoboyowa DA; Alausa AO; Atasie NH; Ilesanmi A; Dairo G; Tiamiyu ZA; Batiha GE; Alkhuriji AF; Al-Megrin WAI; De Waard M; Sabatier JM
    Front Chem; 2022; 10():964446. PubMed ID: 36304744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
    Balkrishna A; Mittal R; Arya V
    Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
    Vardhan S; Sahoo SK
    Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective inhibition of coronavirus replication by
    Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
    [No Abstract]   [Full Text] [Related]  

  • 29. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.
    Patel D; Athar M; Jha PC
    J Biomol Struct Dyn; 2022 Apr; 40(7):3071-3081. PubMed ID: 33200683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
    Rahul S; Sarkar A
    J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
    Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
    Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Sanachai K; Mahalapbutr P; Sanghiran Lee V; Rungrotmongkol T; Hannongbua S
    J Phys Chem B; 2021 Dec; 125(50):13644-13656. PubMed ID: 34904832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
    Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S
    Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures.
    Shen Z; Ratia K; Cooper L; Kong D; Lee H; Kwon Y; Li Y; Alqarni S; Huang F; Dubrovskyi O; Rong L; Thatcher GR; Xiong R
    bioRxiv; 2021 Feb; ():. PubMed ID: 33594371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies.
    Azeem M; Mustafa G; Mahrosh HS
    Int J Immunopathol Pharmacol; 2022; 36():3946320221142793. PubMed ID: 36442514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular modelling on SARS-CoV-2 papain-like protease: an integrated study with homology modelling, molecular docking, and molecular dynamics simulations.
    Arwansyah A; Arif AR; Ramli I; Kurniawan I; Sukarti S; Nur Alam M; Illing I; Farid Lewa A; Manguntungi B
    SAR QSAR Environ Res; 2021 Sep; 32(9):699-718. PubMed ID: 34392751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synonymous and Biased Codon Usage by MERS CoV Papain-Like and 3CL-Proteases.
    Kandeel M; Altaher A
    Biol Pharm Bull; 2017 Jul; 40(7):1086-1091. PubMed ID: 28420819
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Huynh T; Cornell W; Luan B
    Front Chem; 2020; 8():624163. PubMed ID: 33614597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of bio-active food compounds as potential SARS-CoV-2 PLpro inhibitors-modulators via negative image-based screening and computational simulations.
    Bhowmick S; AlFaris NA; Zaidan ALTamimi J; ALOthman ZA; Patil PC; Aldayel TS; Wabaidur SM; Saha A
    Comput Biol Med; 2022 Jun; 145():105474. PubMed ID: 35395517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based inhibitor design and repurposing clinical drugs to target SARS-CoV-2 proteases.
    Narayanan A; Toner SA; Jose J
    Biochem Soc Trans; 2022 Feb; 50(1):151-165. PubMed ID: 35015073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.